DocuSign Envelope 1D: 3096429-9B0 AESS AIAG. 60F635742G1

PUBLIC HEALTH SERVICEPATENT LICENSE-NON-EXCLUSIVE
This Agreement is based on the model Patent License Non-exclusive Agreement adopted by the U.S. Public HealthService (“PHS) Technology Transfer Policy Board for use by components ofthe National Institutes of Health(“NIN the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration(“FDA”), which are agenciesof the PHS within the Departmentof Health and Human Services (“HHS”).
This Cover Page identifies the Paris o this Agreement:“The U.S. Department of Health and Human Services,as represented by“The National InstituteofAllergy and Infectious Diseases
an Institute or Center(hereinafter referred 0 a the “NIAID") oftheNii
andModerna, Inc,
hereinafier refered to as the “Licensee”,
having offices
at200 Technology Square, Cambridge, MA 02139
created and operating under the lawsofDelaware
Tax ID No: 270226313

NI License Application Number A.286-2020
Final
14 December 20221DocuSign Envelope 1D: 3096429-9B0
AESSAIAG.60F635742G1

For the NIAID intemaluseonly
License Number: L-049-2023-0
License Application Number: A-286-2020
Serial Number(s) of Licensed Pateni(s) or Patent Application(s): See Appendix A
Licensee: ModemaTX, Inc.
Cooperative Research and Development Agreement (CRADA) Number(fasubject invention):NA
Additional Remarks:
NA
Public Benefi(s): Developmentof vaccine
oprevent SARS-CoV-2 infection andorCOVID-19disease“This Patent License Agreement, hereinafler refered (0 as the *Agreement”, consistsof this Cover Page, an atached
Agreement,a Signature Page, Appendix A (List ofPaten(s)orPatent Application(s). AppendixB(Fieldsof Useand Territory), Appendix C (Royalties). Appendix D (Benchmarks and Performance), Appendix E (Commercial
Development Plan), Appendix F (Example Royalty Report), Appendix G (Royaly Payment Opsions), and Appendix
H (Example Royaly Calculation).

NI License Application Number A.286-2020
Final
14 December 20222DocuSign Envelope 1D: 3096429-9B0
AESSAIAG.60F635742G1“The NIAID and the Licensee agree as follows:
I.
11

BACKGROUND
Inthe courseof conducting biomedical and behavioral research, the NIAID investigators,togetherwith
investigators
at Dartmouth College and The Scripps Research Insitute (each, a Partner”), madeinventions that may have commercial applicability.
12 By assignmentofrights from the NIAID employees and other inventors, HHS, on behalf
ofthe
Government, owns or co-owns intellectual property rights claimed in any United Sates or foreign patentapplications or patents corresponding to the assigned inventions. HHS also owns any tangible
embodimentsofthese inventions actualy reduced to practice by the NIAID. Pursuant 0agreementswilh
cachofthe Partners, the NIAID hastheexclusive right o gran licenses to the Partners’ rights in the
Licensed Patent Rights together with those ofthe Government, including the licenses and other rights stforth herein, inaccordance with the terms se forthherein,The Partners continue o maintain an undivided
ownership interest in such patent rights.
13 The SecretaryofHHS has delegated to the NIAID the authority to enter into this Agreement forthe
licensing ofrights 0 these inventions under 35 U.S.C. §§200-212, the Federal Technology Transfer Act of
1986, 15 U.S.C. $3710(a), and the regulations governingth licensingof Govermment-owned inventions,
37 CER. Part 404,
14 The NIAID desires to transfer these inventions o the private sector through commercialization ieenses 0
facilitate the commercial development including commercializaton ofproducts and processes for public
use and benefit.
1.5
The Licensee desire toacquirecommercialization rights tocertainofthee inventions in light ofmarketed
todevelop fo public use and benefit.
products it has and continues
2
DEFINITIONS‘Capitalized terms not otherwise defined herein wil have the meanings set forth below:
20 “Additional License” means an exclusive
ornonexclusive license that includes the Licensed Patent
Rights and i granted10a Third Party who is responsiblefor payinga shareofpatent expenses, andwherein the exclusive or nonexclusive license hasa fieldof use directed to clinical use. Additional
License specificallyexcludeslicenses directed solly 1 evaluation, intemal use or commercialization ofresearch reagents.
22 “Affliate(s" means a corporationo other businessent, whichdirectly
orindirectly is controlledbyor
controls,
oris under commoncontrolwith the Licensee. For this purpose, the term “control” shall meanownershipofmor than ffy percent (50%) ofthe voting stockorother ownership interestofthe
corporation
orother business entity,orthe power ocect
o appoint more than fifty percent (50%)ofthe
membersofthe governing body ofthe corporationor ther business ntiy.
23 “Antigen” means any active ingredient or groupofactive ingredients tht induces an adaptive immune
response specific itself
24 “Benchmarks” mean the performance milestones that are set forth in Appendix D.25 “BLA” meansa Biologics License Application or similar application or submission for marketing approval
filed with or submited
toaRegulatory Authority inconformancewith th requirementsofsuch
Regulatory Authority
NI License Application Number A.286-2020
Final
14 December 20223

Docusign Envicp ID: 3099420-9084E55 ABBF3635F42C1
26“Clinical Trial” meansa Phase | Clinical Trial, Phase 1 Clinical Tris, Phase 11Clinical Trial andlor
postapproval clinical ial.

) rr]
28 “Commercial Development Plan” means thewriten commercalization plan tached as Appendix
29 “Effective Date” means November1,2022
2.00 “First Commercial Sale” means th nial ransfer byoron behalfof the Licensee (including ts
Affiliates)ofLicensed Products
0. Third Party or the iil practice ofa Licensed Process byor on
behalfofthe License or ts Aliasfor aThird Party. in exchange for cas or some equivalent to which
Value canbe asigned for the purposeofdetermining Net Sales,
211 “FDA” means the Food and Drug Adminisirtion.
212 “Government” means the Governmentofthe United States ofAmeric
213 “IND” means an Investigational New Drugapplication,Clinical Study Application, Clinical Trial
Exemption, or similar applicationo submission for approval to conduct human clinical invesigations filedwith or submited 03 Regulatory Authorityo in conformance ofsicha Regulatory Authority.
204 “Licensed Fields of Use” means the fields of
us identifiedin Appendix
215 “Licensed Patent Rights” means:@ patent applications including provisional potent applications and PCT patent applications)orpatents
tedinAppendixA.
alldivisionalandcontinuationsof
theseapplications(including
Subsequent divisional and continuations ofsuch divisional an continuations). ll patents suing
rom thseapplications, divisional, and continuations, and any reissues, reexamination, andextensions ofal thse patents:(4) tothe extent thatthe following contain one
ormore clams directed othe inventiono inventions
disclosed in Paragraph 2.1560)©) continuatonsinepartofParagraph 2.156).
Gi) alldivisions andcontinuationsofthese contintions-in-part;(i) all patents suing from these continuations-i-par, divisional, and©

v) prioritypatentapplication(s)ofParagraph2.15a): nd(©) any ressues, reexamination, and extensions ofal these patents:o inventions
thatthe following containoneormore claims directed othe invention
tthe extentin Paragraphdisclosed
2.15(a): allcounterpart forcign and US. potent applications and patentsto
Paragraphs 2.15(a) and 2.15(b, including hose listed in AppendixA:andNIH License Applicaton Number A286.2020
final
16 December 2022“a.

DocuSign Envelope 1D: 3096429-9B0 AESS AIAG. 60F635742G1

(@

206
207

208
200

Licensed Patent Rights shall not includeclaims ofany patents
orpatent plications in
Paragraphs 2.15(b) o 2.15(¢)o the extent tha such claims are solely directed to new matter thatis not the subject mater disclosed by any patent application covered by Paragraph 2.15(a).
“Licensed Processes” means processes, hat in the courseofbeing practiced. are, or would be ifthe
applicable patent application were to issue withthe scope ofclaims as when filed, within the scope ofone.
or more claims ofthe Licensed Patent Rights.
“Licensed Products” means angible materials, the manufacture, use, sal, importation or ther
exploitationofwhich are, or would beifthe applicable patent application were o ssue with the scope ofclaimsas when fled, within thescopeofone or more claims ofthe Licensed Patent Rights, includingall
products developed through th practiceofLicensed Processes, or the manufacture, use, sale or
exploitationofwhich practicesa Licensed Process. For clarity, Licensed Products that are intended 10, or
actually, require separate pivotal clinical rials will be deemed diferent Licensed Products for the purposes.
ofthis Agreement“Licensed Territory” means the geographical area identified in Appendix B.
Nese)

NI License Application Number A.286-2020
Final
14 December 2022s-DocuSign Envelope 1D: 3096429-9B0 AESS AIAG. 60F635742G1

220
221
222
223

224

“Phase I Clinical Trial” means
ahuman clinical tia including Phase 1a and Ib) in any country that is nota Phase II Clinical Trial, Phase 11 Clinical Trial or post-approval clinical rial.
“Phase I Clinical Trial” meansa human clinical tial(including Phase 2a and 2b) in any county in which
the protocol is designed t include at east one endpoint measuring efficacy (qualitative o quantitative) for
anew indication, but the design is not suficently controlled or sized to suppor regulatory approvalofthe
Licensed Product for marketing“Phase IfClinicalTrial” means, fo the purposesofthis Agreement,
ahuman clinical tial in any
country in which the protocol is designed to support regulatory approval ofthe Licensed Product formarketing.
“Practical Application” means to manufactur in the caseofa composition
orproduct, 10 practice in thecase ofa process or method,orto operate in th caseofa machine or system; and in ach case, under these
conditions
as to establish that the invention s being utilized and that is benefit
aeto the extent permitiedby law or Government regulations available tothepublicon reasonable terms. The Parties acknowledge
and agre tha, asof he Effective Date, th Licenseeorits Affiliate has achieved Practical Application
ofthe applicable invention.
“Pro Rata Share” means oneof the following:(@in instances where the Additional License(s) grantedby NIAID recoverapredetermined
percentageof patent cost, one hundredpercent(100%)ofpatent prosecution costs minus thepercentageof patent prosecution costs recovered by the AdditionalLicense(s) which recovera
pre-determined percentage ofpatent costs. For example, if NIAID has grand an Additional
Tieense tha recovers twenty percent (207%)ofpatent prosecution costs, then the Pro Rata Share
Wouldbeone hundredpercent (100%) minus twentypercent (20%), or eighty percent (80%);(6) in instances where the Additional Licensc(s) granted by NIAID recovera ful Pro Rata Share ofpatent prosecution costs, ane(1)minus the value derived from the number
ofAdditional
License(s) granted by NIAID that recovera ull Pro Rata Share of patent prosecution costs
divided by the total numberof icenses granted by NIAID that recovera ful Pro Rata Share ofpatent prosecution coss. For example, ifNIAID has granted four (4) Additional Licenses thatrecover a full Pro Rata Share ofpatent prosecution costs, then the Pro Rata Share would be, one(1)mins [four (4)divided by five (5), or onefifth (1/5) or(© instances where the Additional License(s) are granted according o the definitionofbothParagraphs 224(a) and 2.24(b, the Pro RataSharepaid byLicenseewill be the value derived
from the Pro Rata Share as determined under Paragraph224(a) multiplied by the value derived
from the Pro Rata Share as determined under Paragraph 2.24(b). For example,ifto (2)Additional Licenses
aregrantedwherein one (1) Additional License recovers twenty percent(20%)ofpatent prosecution costs andone(1) Additional License recovers a ull Pro Rata Shareof patent prosecution costs, the Pro Rata Share would be (one hundred percent (100%) minus
twenty percent (20%) multiplied by one (1) minus (one(1)divided by two (2), or eighty percent(80%) multipliedby one-half (12), equaling forty percent (40%).
225 “Regulatory Authority” means any applicable goverment regulatory authority involved in ranting
approvals for the manufscturing, marketing reimbursement and/or pricing of Licensed Products in the
Licensed Territory, including, in the United States, the United States Food and Drug Administration andany successor or foreign govemmental authority having substantially the same function.
NI License Application Number A.286-2020“6Final
14 December 2022

Docusign Envicp ID: 3099420-9084E55 ABBF3635F42C1
226 “Sublicensee” means
Third Party
0 hom License diel or va an AfterSublcensee) isaedspein sublicense unc the Liens Potent Rigs Teened 1 Lives hereunder ut. i
Eh cae xeuding any Tied Party acting seyasGrout.
227 “Third Paty” means. person rent thr than 4 Lisenseoranyofis Affliates an (4) the NIAID
228“Valid Claim” means

551

amavormns
The NUAID erty gras, efctiv as ofthe Fifi Date, nd the Licensee aceps on bala self
and ts Ate, Sujet fo he es and condiions fs AER, 3 none ese under teicensd Patent Rights ih Licensed Taritory for License nd 1ATs 0 make an hve mace
Lou nd have used to rte and have Id fo sell and hae od To oe
1Se, and pon
0 export an Licensed Products he Licensed Fic of Use and to praciee and hve practiced ny
ceased Proctsc nt Licensed Fids of Us
52 “Tis Agreement confers no ns rights by implication, opp,
orotherwise ander ny patentolcaion or pret of he NAT or a othr Perso o any lin the Partners oer hn he
ViCenaed Patent Fight regres whthr then poem appliaionsof pets re domo
Sibordinte toh Licensed Patent Right. Except ao permed unr 33 USC. § 711, ner the
License nor ay fos Atewill eo procice ah License Potent Rights outid th scopeofor
Cherise not incompliance wih he righ a nse famed 1h Liens and fs Aes underhs Agreemen.
33 heLicense wishes 0 amend he Liens Fis af Us to include adionl feds odin forEE
and submitio
NATE Commerc Delopmen Fm STBene marks ieLicensewillft () nce thepepe
dosclopmont
sci heforth Licensed Products hath Licenses o ts Afi proposes 0 onduet in Soh proposed
ional Tels dictions and (5) rcasorably acceptable 0 the NIAID, Upon cit he NIAID
oFSucha Commercial esclopment Pan and Benchmarks hare rescndy accept toh NIAID.
the Parties wil ter iioan amendmen this Agreement at nclude a update 10 he Licensed Fie
OF Coe commensurae withthe scope fhe adidonl feds o dations that are he sue of ch
Commarea Devcopment Pian. and i ate 1 Appendices
D(Benchmarks and Pefomancer and E(Commercial Developmen Pan reflect he addition fo the Liensed FieksofUse.

Ni License Application Number A286.2020
Fol
4 oecember 2022aDocuSign Envelope 1D: 3096429-9B0 AESS AIAG. 60F635742G1

|
4.
4.1

42

43

44

45

SUBLICENSING
Solely with respect any sublicense agreement with any Third Party, upon writen approvalby the
NIAID, which shal include prior reviewof any such sublicense agreement by the NIAID fora period offifteen (15) business days, andwhich approval shall notbeunreasonably conditioned, withheld
ordelayed
bythe NIAID, the Licensee orits Affliates may enter ino sublicensing agreements under the Licensed
Patent Rights only when it concurrently licenses proprietaryor in-licensed intellectual propertyrighs withrespect 10:3 Licensed Product. For the avoidanceofdoubt, neither the Licensee nor any of its Affiliates
ave the right to soley sublicense the Licensed PatentRightson a standalone basis. Inreviewing any
proposed sublicense agreement, the NIAIDwill keep th termsofsuch proposed sublicense agreement
confidential, to the extent providedforby law
The Licensee and any ofits Affliates agree that any sublicenses granted by the Licensee or any such
Affilate shall include confidentiality and nonuse provisionsat leatasrestrictive as those set forth in this‘Agreement, shall be consistent wilh and subordinate to the termsofthis Agreement, and shall provide thatthe applicable terms and conditionsof this Agreement, including the obligations o the NIAID set forth inParagraphs 5.1-5.2,8, 10.1102, 11.1, 12.6, 13.7-13.9 and 14.10ofthis Agreement,
shallbebindingupon
the Sublicenseea i it were a party to his Agreement. The Licensee and its Affliates further agree totach copiesof these Paragraphs to all sublicense agreements
Any sublicenses grand by the Licensee or and any ofits Affliates shall provide for the terminationofthe
sublicense, or the conversion
toa license directly between the Sublicensees and the NIAID, at the option
ofthe Sublicensce, upon termination of his Agreement under Article 13. This conversion is subject fo the
NIAIDapproval (notto be unreasonably withheld, delayed or conditioned) and contingent upon acceptanceby the Sublicenseeofthe remaining provisions ofthis Agreement.
The Licensee agrees, and will caus is applicable Affliate, to forward to the NIAID a tre and complete
copyof each fully executed sublicense agreementpostmarked within thirty (30) days afer the execution ofsuch sublicense agreement. To the extent permited bylaw,the NIAID agrees 0 maintain each sublicense
agreement in confidence, except that the NIAID may share each such sublicense agreement with ts
Partners, provided the Partners are bound by non-use and non-disclosure obligations that are no lessrestrictive than those set forth herein.
Notwithstanding any sublicense to any Third Party, ModemaTX, In. will remain responsible 0 the
NIAID for the perfomance of
al ofthe Licensee's anditsAffliates’ obligations under, and compliancewith, all applicable tems and conditionsof,this Agreement, including any obligations delegatedto itsSublicensees or wilh espect 10 any rights exercisedorobligations performed by any Affliate of
ModemaTX, Inc.

NI License Application Number A.286-2020
Final
14 December 2022“8DocuSin Envelope 0: 690004263808
4E55ATSOF HSGFAZCT
5.
S11
52
6
6
62
63
64
65
66
67

68

STATUTORY AND NIH REQUIREMENTS AND RESERVED GOVERNMENT RIGHTSThe NUAID acknowlsdges to the Licensee o is Aft has povided the NIAID with Licensed
Products
ormater made rh he Licensed Poses for rscarch se,
The License onbehalfofland is Aliates) ages tht produces sec or od n the nied Sts
cmboding Licensed Product or produced rough seofLicensed Processes shall be manufciured
sania nh United Ses ules
awriten war 5 obsined in ance fom he NIAIDROVALTIESAND REIMBURSEMENT
The Licensee agrees
0pay the NIAWD the noncrdiable nonrefundablePr Effcive Dae Royals as
et oth in Append.
The License agrees
0pay he NUAID a imu amu oyslhy a et Forth in Append C.
Th License agrees
0py he AID smd royale 3 ct forth in Appi C.
The Liens ages
0py the NAD Benchmark royals st forth n ApendixC.
Nomulipe royale shall be payable because any Licensed Products or Licensed Processes ar within
Ih opeofmor han oe fn Licensed Patent ight
Onsale of Licensed Product by the Licence o ts Afflineso Sublicnsees made n the than anmeng rsa, hE valuofhe Net Salestuted under his Al fo his rnsactionshallbe:
hat whichth LicensetsATTateor Sublcenses (3 aplcale) would hae ecfvd nan
men rato, bse on Sisof1 Quan, nd Qa prods on or shout he Gmofhis
ramacionWith regard to uneimbursd expenses associated with he rearton, lin, rosccution, ad macrance
ofall tent sppcatons and pans included within the Lice Patent Rights and pi by he NIATD
NIAID 5 3n
Licence shallotisafcAgreement,
i oftheprior
ionalheroy,
whiTal$ysiatr(60 days
the NEAID'shesisson
af poythrssosbly dese writ
Stent and request for payment
th Licensee, an amount cuialet 0.3 Po Rata Shareof theuneimbursed patent expenses previously pid by the NIAID. The Licence’ obligation under his
Panera 7 Shall mt ened uncimbured pense previously pid he
NIAID.
With regard to uneimbursd expenses associated with he preparation, lin, rosccution, ad macrance
ofll tent spcations ad pans included within te License Patent Rights and pid by he NIATD
anor ae the ai ofthe nt iar o this Agreement, the NIAID. fn ts ole discretion, may require
he Liens
10 payth NIAWD on sn ama bass, within sixty (60) dysaf the NIAID subsion fa
esonably deal writen stent and request for payne a royalty mount cual 0 the
Pra Rata Sharofthes ursimburicd pense paid during he previous calendar Sr:
10hepaythPro
Rate Shareoftheseohanda noimthecpl
NIAID
to handic
thse unctions.usm
Howser, i expenses
hs ven.dict
the NIAID
Licenseeby
halle th clin ofth lw fn ox

NH License Application Number A286 2020
Fal
34 December 2022-

Docusign Envelope ID: 30904205085 AB
SFIB35F4ZC1(©

under exceptional circumstances, he Licensee may be given the righ 0 assume responsibil forthe preparation, fling, prosecution, or maintenance of any patent applicationo patent included
Wilhth Licensed Patent Rightspovided
ha he Licensee shal nothaveany obligation 0
assume such responsibility. In that event, the Licensee shal diecly pay the tomeso agents
engaged 0 prepare, fie, prosecute, or maintain these patent applications or patents and shalprovide the NIAID wih copieofeach invoice asociaed with these services as well a.
documentation tht these invoices ave been paid.
he Lieve’ hlgaion under is Faagrph8 ll os exesed OFT
ridunreimbursed expenses paid by the NIAID on or afer the datof the TRAT TERT TOTAgreement.
69 The NIAID agrees, upon writen request, fo provideth Licensee with summariesofpatent prosecution
invoicesfor whic the NIAID has requested payment from th Licensee under Paragraphs 67and 6. The
Licensee agree (on behalf
ofisland it AMTate) that al information provide by the NIAID refed 0
costsshallbe rated asconfidential commercial information and shall no bereleased fo
patentprosecutiona Third Party other thn 0 the Licensee’ Sublicensee(son a necc-to-Know basis andaconfidentialcommercial information), exceptas requiredby la oracourofcompetentjurisdiction.
7. PATENTFILING,
PROSECUTION.
ANDMAINTENANCE“The NIAID ages to take responsibility fo the preparation, lin. prosecution, and maintenance ofany
and all patent application
orpatents included in he Licensed Patent Rights.
8RECORDKEEPING
The Licensee agrees to keep (and to cause fs Afliaes and Sublicensees 0 keep) accurate and correct
recordsof Licensed Products made, used, sold, offered forsale, imported or exparted and Licensed
Processes practiced under tis Agreementonorafer the Effective Date appropiate(0determine theamount of royalties due the NIAID. These records shall be retained for at est five 5) years following agiven reporting period and shall be availabe during noma business hours for inspection, at the expense of
he NIAID, by an independent, certified accountant orothrdesignated auditor selected by the NIAID forthe sole purposeofverifying reports and royaly payments hereunder. As a condition 0 examining any
recordsof the License, such accountant
or audior must have executed and delivered the Licenseea
confidentiality agreementas reasonably requested
byth License. Ifan inspection shows anunderreportingor underpayment in excess of five percent (5°) for any twelve (12) month period then the
Licensee shal reimburse the NIAID for the costof the inspection at he time he Licenseepays theunreported rallies, including any adiional royals as required by Paragraph7. All oyaly payments
required under his Paragraph shallbedue within sity (60)daysofthe date the NIAID provides he
Licensee notice ofthe payment due. All such underpayment shal be subject 0 th interest rat set forth inParagraph 9.7.
9. REPORTSONPROGRESS.BENCHMARKS.SALES,ANDPAYMENTS
9.1 Priorto signing this Agreement, the Licensee
or its Affilate has brought the Licensed Patent Rights 0he point ofPractical Application. I adition, the Licensee has provided he NIAID withthe
Commercial Development Plan in Appendix E, under whic the Licensee (iseorthrough ts Altes)
intends 10 se commercially reasonable efforts 10 bring the subject matter ofthe Licensed Patent Rights 0
additionalPractical Applicaton. This Commercial Development Plan is hereby incorporated byreference into this Agreement. Based on his plan, performance Benchmarks are determinedas specified
in Appendix D
92 The Licensee shall provid writen annual, high-level summary reports on is product development
progresorefforts 0 commercialize under the Commercial Development Plan for eachofthe Licensed
Fields ofUsewithin sity (60) days after December
31 ofeachcalendar year. These progress reports shall
NIH License Application Number 2862020
“0.
Final
14 December 2022

DocuSign Envelope 1D: 3096429-9B0 AESS AIAG. 60F635742G1

include, but not be limited 0: progress on research and development, statusofapplications for regulatory
approvals, manufacture, marketing, importing, and sales during thepreceding calendar year, aswell15
plans for the presentcalendar year. The NIAID also encourages these reports
to include informationonanyof he Licensee's
orits Affliates” public service activities tha relat o th Licensed Patent Rights.
Ifreported progress differs from that projected n the Commercial Development Plan and Benchmarks,
the Licensee shall explain the reasons for such differences. In any annual report, the Licensee may
propose amendments to the CommercialDexelopment Plan, acceptanceofwhich by the NIAID may notbedenied unreasonably. The Licensee agrees, andwill cause its Afflates, to provide any additional
information reasonably required by the NIAID to evaluat the Licensee's performance under thisAgreement. The Licensee may amend the Benchmarksa any ime upon writen approval by the NIAID,“The NIAIDshall not unreasonably withhold approvalofany requestofthe Licenseeto extend the time.
periods ofthis schedule
ifthe request is supported by areasonable showing by the Licenseeofdiligence ints performance under the Commercial Development Plan snd toward bringing the Licensed Products tothe point of Practical Application.
93 The Licensee shall report to the NIAID the dates for achieving Benchmarks specified in Appendix D and
the First Commercial Sale in cach country i the Licensed Territory within thiry (30) days after such|
9.5

Royalties due under Article 6 shall be paid in U.S. dollrs and payment options are listed in Appendix G.
For conversion of foreign currency to U.S. dollars, the conversion rat shalbe the New York foreignexchange rate quoted inTheWallStrcetJournal, o by another reputable, elable, indusiy-recognizedsourceofaccurate conversion rate tha are not materially different fom the conversion rates quoted by
The WallStreet Journal, on the day that the revenue is recognized by the Licensee
or its Affliates or‘Sublicensees,asaplicabe, and any lossofexchange, value, axes, orotherexpenses incurred in the transfer
or conversion toU.S. dollars shallbepaid entirely by the Licensee. The royaly report required by
Paragraph 9.4 shallbe mailed
tothe NIAIDat ts address for Agreement notices indicatedon the Signature
Page.

NI License Application Number A.286-2020
Final
14 December 2022cn.

Docusign Envicp ID: 3099420-9084E55 ABBF3635F42C1
9.6

The Licensee shalbe solely responsiblefordetermining iany tax on roa income s wed ouside theUnited Sises and shall poy this to andberesponse foal Flings with appropriate agencies of foreign
sovemmens The Licensee may not deduct
orwilhhld from any amounts payable under 5 Agreement
any taxes that i requiredby applicable lw to deductowithhold. including from subsequent payments
made pursuant hs Agreement. Inthe event tht the License is required to make any ings with any
Torenjurisdiction to avoid being subject
towithholdingtax in any urdicion outside the United Sates
teganding amounts payablebusedon his Agreement, he the Licensee shall
bedircly responsible forihe payment ofany reasonable and documenied cxpenscs of sch ings, andshall make poymentofsuch
amounts within sity (60) days followin receiptofan invoice and rlted supporting documentation
97 Addional royale maybeassessed by the NIAID on any payment payable hereunder that is mre thanPO
pedwcammalmeo®
Bm
Totem
ate
Te By pAb T Ieever TessTI Tre ie ayBe apd refoactivel
from theoriginal due date unt the date of eceptby the NTAID ofthe overdue payment nd additonal royale.
“The payment ofany addtional royalties stall not prevent the NIAID fom exercising any the rights
may have a5 a consequenceofth lainessofany payment.
98 All plans and reports required by this Aric
9and marked “confidential” bythe Licensee shal theextent permed by a,be estedby the NIAND
a commercial and financial information obiaied fom aperson and as privilege and confidential: provided that the NIAID may shre al such plans and reports
ith 5 Partners on aconidialbasi with non-disclosure and non-use obligations a est os restrictive
as those st forthherein,and any proposed disclosure ofthese records by the NIAID under the Freedom ofInfomation Act (FOIA) S U.S.C: $552 hal be subject othe prdislosure notification requirments of 5
CFR. §5.65(d).

10.

PERFORMANCE

102 The Parties acknowledge and agree that the License has achieved Fist Commercial Sale, and uni theexpiration or termination ofthis Agreement, the Licensee shal use reasonable commercial forts tocontinue
tomake Licensed Products and Licensed Processes reasonably sccessibe fothe United States
public10.3 TheLicense agess, tothe extencommercially resonable, to makereasonablequantis of Licensed
Products
ormaterials produced through he use of Licensed Processes availble
opatent assistanceprograms.
10.4 The License agrees, as part of ts marketing and product promotion o develop edcaronal matricbrochures, website ci.) directed to patients and physicians detailing he Licensed Products or medical
aspectsof he prophylactic and therapeutic uses ofthe Licensed Products.
10.5 The License agrees to suply (1 the extent not already supplied). tothe Technology Transfer andIntellectual Property Offic, NIAID, athe mslng adress 601 Fishers Lane. Suite 6D, Rockville, MD.
20852-3804 US A. with inert samples ofthe Licensed Products or Licensed Processes
ortheir
packagingfo educational and display purposes nly.
NIH License Application Number A286.2020“12inal
14 December 2022

DocuSign Envelope 1D: 3096429-9B0 AESS AIAG. 60F635742G1

Il.
ILI
112

INFRINGEMENT AND PATENT ENFORCEMENTThe NIAID and the Licensee agree to noify ach other promprly ofeach infringement
orpossible:
infringementofthe Licensed Patent Rights,as well as any facts that may affect the validity, scope, or
enforceability ofthe Licensed Patent Rights of which either party becomes aware.
Inthe event that adeclaratory judgment action alleging invalidityof anyofthe Licensed Patent Rights
shallbebrough against the NIAID, the NIAID agrees
onoify the Licensee that an action alleging
invalidity has been brought. The NIAIDdoes not represent tha itshalcommence legal action o defend
againstadeclaratory action alleging invalidity. Neither the Licensee nor any ofits Affliates shall take any
action to compel the Government or thePartners ether to initiate or tojoi in anydeclaratoryjudgment
action. Should the Government or the Partnersbe madepartytoany declaratory judgment action
alleging invalidity ofany ofthe Licensed Patent Rights by motionor anyothe action ofthe Licensee or
its Affliate, he Licenseeshalreimburse the Government and the Partners for any coss, expenses, orfees, which the Government o the Partners incur as a result ofthe motion or othe action. Upon the
Licensee's paymentofall costs incurred by the Government and the Partners
as a result of Licensee's
adefault in theorother action, theseaction by the Licensee shalno beconsideredjoinder motion
performance ofany material dbligation under this Agreement.

| IR
12. NEGATIONOF
WARRANTIESANDINDEMNIFICATION
12.1 The NIAID offers no warranties other than those specified in Article |.
122 The NIAID docs not warrant the validity or enforceability ofthe Licensed Patent Rights and, except as
set forth in Article1, makes no representationsorwarranties whatsoever with regard to thscope
ofthe
Licensed Patent Rights, or that the Licensed Patent Rights may be practiced without infringing otherpatents or other intellectual property rights ofThird Parties
123 EXCEPT AS EXPRESSLY SET FORTH IN ARTICLE 1,THE NIAID MAKES NO WARRANTIES,EXPRESS OR IMPLIED, INCLUDING OF MERCHANTABILITY, NON-INFRINGEMENT ORFITNESS FOR A PARTICULAR PURPOSE OF ANY SUBJECT MATTER DEFINED BY THE
CLAIMS OF THE LICENSED PATENT RIGHTS OR TANGIBLE MATERIALS RELATED.
THERETO.
124 THE LICENSEE ACCEPTS THE LICENSED PATENT RIGHTS AND THE LICENSEDPRODUCTS “AS IS", AND THE NIAID DOES NOT OFFER ANY GUARANTEE OF ANY KIND.
12.5 The NIAID docs not represent that i shall commence legal actions against Third Parties infringing the
Licensed Patent Righs.
NI License Application Number A.286-2020
13Final
14 December 2022

DocuSign Envelope 1D: 3096429-9B0 AESS AIAG. 60F635742G1

126

127
13.
13.1
132
133
134
135

The Licensee shall indemnify and hold the NIAID, the Partners, and thei respective employees, officers,
dirctors, students, fellows, agents, and consultants (collectively,“Indemitees”) harmless from andagainst al lability, demands, damages, expenses, and losses, including but no limited to death, personal
injury, illness, or property damage, in ach case to the extent arising outofThirdParty clims asserted
against Indemnitees in connection wih or arising out of:(@) the use byoronbehalfofthe Licensee or its Affliates or Sublicensees,o ts and their respective
directors, employees or agents,ofany Licensed Patent Rights or Licensed Processes:(8) the design, manufacture,distribution, or use ofany Licensed Products, Licensed Processes ormaterials by or onbehalfofthe Licensee or it Affliateso Sublicensees. or its and theirrespective directors, employees
or agent, or other products or processes developed in connection
with orarising out of the Licensed Patent Rights; or(©) the Licensee's or its Affliates” or Sublicensees’ gross negligence,orwillful misconduct, breachofapplicable law, or breachof this Agreement“This Paragraph 12.6 shall not apply if it changes
ornegatively impacts in any way Licensee's
protections under the Public Readiness and Emergency Preparedness Act (Public Law 109-148,
Division C, §2), including any declarations and/or amendments related thereto, oF th extent
any such indemnifiable claims result from NIAID's gross negligence.
The Licensee agrees to maintain a lability insurance program consistent with sound business practiceincluding products liability insurance, wth reputable and financially secure insurance carriers (or pursuant
0: programofself-insurance reasonably satisfactory 10 the NIAID) to cover is and its Afilates”
indemnification obligations.
TERM,
TERMINATION,
ANDMODIFICATION OF RIGHTS
When signedbyallparties, this Agreement will beeffective a of the Effective Date, and shal extendto
the expirationofthe last expireofthe Licensed Patent Rights unless sooner terminated as provided in
his Article 13
Inthe event thatthe Licensee or ts Affiliate commits a material breach ofa covenant or provision under
this Agreement, andifthe breach has not been remedied within ninety (90) days afe the dateof notice inwritingofthe default, then the NIAIDmay terminate this Agreement
by writin notice and pursue
outstanding royalties owed through procedures provided by the Federal Deb Collection Act.
Inthe event thatthe Licensee becomes insolvent, files
apetition in bankruptcy, has such apetition filed
against it, determines to fle a petition in bankruptcy. or receives notice of a Third Party's intention to fle
an involuntary petition in bankruptcy, the Licensee shall immediately notify the NIAID n writing.
The Licensee shall haveaunilateral right to terminatethis Agreement in its entirty by giving the NIAID
sity (60) days" written noice to that effect
The NIAID shall specifically hav the right to terminate or modify,a its option, this Agreement, if
Licensee:@ isnot executing the Commercial Development Plan set forth on Appendix Dand the Licensee
cannot otherwise demonstrat o the NIAID's satisfaction tht the Licensee has taken, or can be.
expected 0 take within areasonable time, effective steps fo achieve Practical Application ofthe
Licensed Products or Licensed Processes:(8) has not achieved the Benchmarks as maybe modified underParagraph 9.2;

NI License Application Number A.286-2020
Final
14 December 2022

14

DocuSign Envelope 1D: 3096429-9B0 AESS AIAG. 60F635742G1(©

haswillully madea flse statementof,orwilfully omitted,
amaterial fact in th license
application or in any reportrequiredby this Agreement;(@ has committedamaterial breach ofa covenant or provision under this Agreement, which
termination willbepursuant
oSection 13.2:(©) is not using reasonable commercial efforts to keep Licensed Products or Licensed Processes
reasonably available to thepublic afr First Commercial Sale:(0 cannot reasonably satisfy unmet health and safety needs;(8) cannot reasonably justify a failure to comply with the domestic production requirement of
Paragraph 5.2, unless waived; or(1) has been found by a courtof competentjurisdiction to have violated the U.S. Federal atirust
laws in connection with its performance under this Agreement.
Notwithstanding any provision to the conrary set fort i this Agreement, in consideration for Licensee's activites
with respec to the exploitation ofLicensed Products in the Licensed Fields of Use as ofthe Effective Date, the
NIAIDwillnot have the right to terminate or madify this Agreement solely with respect
tothe Licensed Fields ofUse
asofthe Effective Date pursuant0 the following Paragraphs: 13.5(2), 13.5(b) 13.5(¢,or 13.5(), and NIAID
hereby affims that he Licensee's activites with respect 0 the exploitation of Licensed Produc in the Licensed
Fields of Use as ofthe Effective Date, stisfis cachofthem. Accordingly, NIAID wil not have the right toterminate or modify ths Agreement pursuant
tothose Paragraphs.
136 In making the determination whether
to terminate or modify this Agreement under Paragraph 13.5, the
NIAIDshall take into account the normal courseofsuch commercial development programs conducted‘with sound and reasonable busines practices and judgment and the annual reports submited by the
Licensee under Paragraph 9.2. Prior to invoking termination or moifcationofthis Agreement underParagraph 13.5, the NIAID shalgive writen noice(0the Licensee providing the Licensee specific notice:of, anda ninety (90) day opportunity
10cur, he breachofther circumstances referenced in Paragraphs13.5(a)-13.50h). If he Licensee fils 0 effect such cur as (0 the tems referenced in Paragraphs. 13.5(a13.500) or fails 0 initiate corrective action 0 the NIAID reasonable satisfaction, then the NIAID may
terminate this Agreement
137 The NIAID reserves the right according to 35 U.S.C. §209()3) to terminate or modify this Agreement if
itis determined that the action is necessary (o meet the requirements for public use specified by federal
regulations issued after the dateofthe license and these requirements are no reasonably satisfied by the
Licensee.
138 Within thirty (30) days ate receiptofwriten notice of the NIAID's unilateral decision to maify or
terminate his Agreement, th Licensee may, consistent with the provisionsof 37 C.F R. $404.11, appeal
the decision by written submission tothe designated the NIAID official. The decisionofthe designated
NIAID oficial shallbe the final agency decision. The Licensee may thereafter exercise any and alladministrative orjudicial remedies thatmaybeavailable.

NI License Application Number A.286-2020
Final
14 December 2022

“ise

DocuSign Envelope 1D: 3096429-9B0 AESS AIAG. 60F635742G1

139

14.
14.1
142
143
144
145
146

Within ninety (90) days after expiration of tenmination ofthis Agreement under tis Article 13, final
report shalbesubmited by th Licensee. Any royalty payments, including those incurred but not yet paid
(such as the full minimum annual royalty), and those elated to patent expense, due to the NIAID shallbecome immediately due and payable upon termination
or expiration, and the Licensee shall pay all suchamounts no later than sixty (60) days afer submissionofsuch final report. Unless otherwise specificallyprovided for under this Agreement, upon termination of this Agreement, (2)allrights and licenses granted
to the Licensee and its Affiliates hereunder shall ease and the Licensee and ts Affliates will no longer
avea license 0 sell offer for sale, distribute, import, export, or manufactur the Licensed Products.
except tha following the effective datoftermination ofthis Agreement, the Licensee and ts Affliates
shallbelicensed o continue
0sell offer forsale,distribute, import, and exports existing inventoryof theLicensed Productsforso ong as such product remains in compliance with is specifications, including its
expiration date, during which time all salesofthe Licensed Product wil be included as Net Sales and all
payment and reporting terms under this Agreement shal continue to apply in full force and effect during
such period: and (b) following the expirationofall Licensed Product remaining, as ofthe elective date of
terminationofthis Agreement, in the Licensee's
orits Aflates” inventory,
the Licensee and is
Affliates shall not have any license under this Agreement 0 sel, offer for sale, distribute, import, andexport such expired Licensed Product. The Licensee may not be granted addiional NIAID licenses ifthe
final reporting requirement is not fulflied.
GENERALPROVISIONSNeither Party may waive or release any ofitsrightsor interests in this Agreement except in wring. The
flue ofthe Government to asserta righ hereunder of 0 insist upon compliance with any term or
conditionof this Agreement shal not constitute a waiveroftha right by the Governmento excuse a
Similar subsequent file to perform anyofthese termsorconditions
by the Licensee.
This Agreement constitutes he enire agreement between the Licensee and the Government relatingtothe subject matter ofthe Licensed Patent Rights, Licensed Products and Licensed Processes, and allprior negotiations, representations, agreements, and understandings are merged int, extinguishedby,andcompletely expressedby his Agreement
The provisions ofthis Agreement ae severable, and i the event that any provision ofthis Agreement
shallbedetermined
obe invalid or unenforceable under any controlling body ofaw, this determination
shall not in any way affect the validity
orenforceabilityofthe remaining provisionsofthis Agreement.
Ifcither Party desires
amodification to this Agreement, then the Parties shall, upon reasonable notice ofthe proposed modification by the Party desiring the change, confer in good faith 0 determine thedesirabilityofthe modification. No modification shallbe effective until awriten amendment is signed by
the signatories o this Agreement o their designees.
Theconstruction, validity, performance, and eect ofthis Agreement shallbegovernedby Federal law asapplied by the Federal courts in the DistrictofColumba.
All Agrecment notices required or permiticd by this Agreement shall be given by prepaid, firs class,registered or certified mailo by anexpress overnight delivery service provided by a commercial carer,
properly addressed to the other Party a th address designated on the Signature Page, or 1 any otheraddress as may be designated in writing by such other Party. Agreement notices shal be considered
timely ifsuch notices are received on or before the established deadline date or sento or before thedeadine date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial carrier
Parties should requesta legibly dated U.S. Postal Service postmark or obtain a dated receipt from acommercial carriero the U.S. Postal Service. Private metered postmarks shall not be acceptable as proof
oftimely mailing.

NI License Application Number A.286-2020
Final
14 December 2022

“16.

DocuSign Envelope 1D: 3096429-9B0 AESS AIAG. 60F635742G1

147This Agreementshal nobeassigned
orotherwise transfered (including anytransfer by legal process orby operation of aw, and any transfer in bankruptcy or insolvency, or in any other compulsory procedure ororderof court) except
0th Licensee's AfMliate(s) ora successorofall or substantiallyallof
Licensee's business to which this Agreement relate, without the prior writen consentofthe NIAID, not
10 be unreasonably withheld, delayedorconditioned ind any assignment in violationoftis Paragraph 14.7
shall be nuland void. Any successor orassigneeof ightsorobligations permitied under this Agreement
will in writing 10 the other party, expressly assume performanceofsuch rights
orobligations. Any
permitted assignmentofthis Agreement wilbebindingon the successorsofthe assigning party. Any
assignment
orattempted assignment by either arty in violationofthe termsofthis Paragraph 14.7willbe
null, void, andofno legal eect. The partes age that th idenityofthe parties is material © theformationof tis Agreement and tht the obligations under this Agreement are nondelegble except asprovided in Article 4 and this Paragraph 14.7. In the event that the NIAID approves
aproposed
assignment the Licensee shall pay the NIAID, as an additional royaly, onepercent (17%) ofthe aie market
Valueofany consideration receivedfo such assignmentofthis Agreement within sixty (60) days afer theassignment
148 The Licensee acknowledges that it is subject to and agrees to abide by the United States laws andregulations (including the Export Administration Act of 1979 and Amns Export Control Act) controlling theexport oftechnical data, computer software, laboratory prototypes, biological material, and othercommodities. The transfer ofthese items may requirea license from the appropriate agencyofthe
Government
orwritten assurances by the Licensee tht it shall not export these items (0 certain foreigncountries withoutprior approval ofth agency. The NIAID neither represents tha license isof is not
required or tha, required, it shallbeissued.
149 Neither Party will make anypressrelease or other public statement regarding the termsof this Agreement
or the subjectmaterhereofwithout the prior writen approval ofthe otherParty: providedthat nothing.
willrestric either Party from disclosing the existence ofthis Agreement. Afe the issuanceofany suchpress relase or any other permited public disclosure by a Party, the disclosing Party may makesubsequent public disclosures reiterating such information without having to obain the other Party’ priorapproval so long asthe information i such press release or other public announcement remains rue,correct, and the most current information with respect
1 th subject matters se forth therein. Forclarity.
ther Party may disclose, and nothing st forth herein will imit either Party from so disclosing, the terms
ofthis Agreement,
orthe subject matter hereof(a)10 the extent required to comply withthrules andregulations promulgatedby the United Stats Securities and Exchange Commission or any equivalentforeign agency of regulatory body, or otherwise required by judicial or administrative process; provided
hat such Party will first provide
acopyof he proposed disclosure to the other Party as fa in advance ofsuch disclosure as is reasonably practicable under the circumstances and reasonably and in good-faithconsider the other Party's comments and requests o limit such disclosure, (b) in connection with any tax
lingorgrant application, subject o reasonable expectationsofconfidentiality where practicable, and (c)in connection with any ligation,
orcongressional request oro comply with any othe applicable law or
requirementofthe Government.
14.10. The Licensee agrees, and will cause its Affiliates, to mark the Licensed Products or their packing soldin the United States with all applicable U.S. patent numbers and similarly to indicate “Patent Pending”
status. All Licensed Products manufactured in, shipped to, or sold in other counties shall be marked ina
maner
topreserve the Licensed Patent Rights in those counirics.
1411 By entering into this Agreement, the NIAID does not directly or indirectly endorse any product or service
by the Licensee whether directly or indirectly related to this Agreement. The
or tobe provided,
provided,
Licensee shall not, nd shall cause tsAffliates not 0,sat or imply that his Agreement is anendorsementby the Government, the NIAID, any other Government organizational unit, or any
Government employee. Additionally, the Licensee shall, and shall cause its Affliates not (0, not use thenamesof the NIAID, the FDA, HHS,
orthe Government or thei employees in any advertising.
promotionalo sales literature without the prior writen approval ofthe NIAID.
NI License Application Number A.286-2020
Final
14 December 2022veDocuSign Envelope 1D: 3096429-9B0
AESSAIAG.60F635742G1

1412 The Parties agree t atiempt 0 site amicably any controversy or claim arising under this Agreement ora
reachofthis Agreement, except for appealsof modifications or termination decisions provided for in
Aric 13.
14.13 Nothing relating
othe grant of license, nor the grant itself, shallbeconstrued to confer upon any person
any immunityfromordefenses under the antitrust lawsor from a chargeofpatent misuse, and theacquisition and useofrights pursuant to 37 C.F.R. Part 404 shal no be immunized from the operation ofstate or Federal law by reason ofthe sourceof the grant1414 Paragraphs 2,3.4,4.5,8,9.49.5(solely with respect to payments due prior toth effective dat oftermination ofthis Agreement or during any sell-off), 6-98, 11.2 except he first sentence threo),
121-126, 138,139, 142, 145, 146, 14.12 and 14.14 ofthis Agreementshalsurvive temninationoftis
Agreement.
14.15 The terms and conditionsofthis Agreement shal, a the NIAID's sol option, be considered by the
NIAID (0 be withdrawn from the Licensee's consideration and the terms and conditionsof this‘Agreement, and this Agreement telobenull and void, unless this Agreement isexecutedby the
Licensee andafully executed original isreceivedby the NIAID within sixty (60) days from the dateofthe
NIAIDsignaturefound at the Signature Page.
SIGNATURES BEGIN ON NEXT PAGE.

NI License Application Number A.286-2020
Final
14 December 2022

18.

OocuSionEnolop 0; 5099476808.4E55AB
SF SSFAZC1

Michael R. Mowatt -S S24: 5 50

by:

ga

DocusignEnvicp ID: 3099420-9084E55ABBF3635F42C1
Offnd Maing Adds oeAgroment cs:
a. re
am
he
PEO
Et
Offi md Mailg air forFr ts
FT —
rt
Sis
Tr

DocuSign Envelope 1D: 3096429-9B0
AESSAIAG.60F635742G1

APPENDIX A= PATENT(S) OR PATENT APPLICATIONS)
Patent(s) or Patent Application(s):US Provisional Patent Application 62/412,703 fled 25 October 2016entitled “Prefusion coronavirus spike proteins
and thei use” [HHS Ref. No. E-234-2016.0-US-01]
PCT Patent Application PCT/US2017/058370 filed 25 October 2017entitled “Prefusion coronavirus spike proteins‘and their use” [HHS Ref. No. E-234-2016-1-PCT-01]
EP Patent Application 178006557 fled 13 May 2019, entitled “Prefusion coronavirus spike proteins and thei use”
[HHS Ref. No. E-234-2016-1-EP-02]
US Patent Number 10,960,070 issued 30 March 2021 entitled *Prefusion coronavirus spike proteins and thei use”
[HHS Ref. No. E-234-2016-1-US-03]
US Patent Application 17/194,834 filed 8 March 2021 ented “Prefusion coronavirus spike proteins and thir use”
[HHS Ref. No. E-234-2016-1-US-04]

NI License Application Number A.286-2020
Final
14 December 2022

ae

DocuSign Envelope 1D: 3096429-9B0 AESS AIAG. 60F635742G1

APPENDIX B- LICENSED FIELDS OF USE AND TERRITORYIL

Licensed Fields of Use:I

Licensed Territory:

UL

Least Developed Countries:

Africa (34): Angola, Benin, Burkina Faso, Burundi, Central African Republic, Chad, Comoros, Democratic
Republic ofthe Congo, Djibouti, Equatorial Guinea, rites, Ethiopia, Gambia, Guinea, Guinea-Bissau, Lesotho,
Liberia, Madagascar, Malawi, Mali, Mauritania, Mozambique, Niger, Rwanda, St Tomé and Principe, Senegal,
Sierra Leone, Somali, South Sudan, Sudan, Togo, Uganda, United RepublicofTanzania, Zambia‘Asia (14): Afghanistan, Bangladesh, Bhutan, Cambodia, Kiribati Lao People’s Democratic Republic, Myanmar,
Nepal, Samoa, Solomon Islands, Timor-Leste, Tuvalu, Vanuatu, Yemen
Latin America and the Caribbean (1): Haiti(Source: United Nations Officeofthe HighRepresentative (UN-OHRLLS) a ofOctober 23, 2013)

NI License Application Number A.286-2020
Final
14 December 20222.

DocuSign Envelope 1D: 3099429-9B0BAESSAIA 60F63574201

APPENDIX C= ROYALTIESRoyalties:|][Jv Dicensee ages pay ©Te NTATD 3 noneredihe, ronrefundable
ToyalTy ThE SOUT OT Four Hundred Million dollars ($400,000;
ooIL

The Licensee agrees to pay to the NIAIDa nonrefundable minimum annual royalty as follows:IL

The Licensee agrees to pay the NIAID carned royalties on Net Sales of Licensed Products in the
Licensed Territory by or on behalf
ofthe Licensee or its Affiliates and any of is or thir Sublicensees asfollows:

NI License Appiication Number A.286.2020
Final
16 December 2022=

DocuSign Envelope 1D: 3099429-9B0BAESSAIA 60F63574201

NI License Application Number A.286-2020
Final
14 December 202224-

DocuSign Envelope 1D: 3099429-9B0BAESSAIA 60F63574201

wo po

[BT
Tove Licensee agrees © pay the NIATD ic Benchmark royalics set forth below [or|Such royally payment Willbe due wiki sixy (60)days ater achieving each such Benchmark.

|NI License Application Number A.286-2020
Final
14 December 2022

5

1

DocuSign Envelope 1D: 3099429-9B0BAESSAIA 60F63574201

NI License Application Number A.286-2020
Final
14 December 2022

26.

DocuSign Envelope 1D: 3096429-9B0 AESS AIAG. 60F635742G1

APPENDIX D - BENCHMARKS AND PERFORMANCE“The Licensee agrees
0use commercially reasonable effort
tachieve the following Benchmarks for its
perfomance under this Agreement and, within thirty (30) daysafer achievinga Benchmark, shal notify the
NIAID that the Benchmark has been achieved:

NI License Application Number A.286-2020
Final
14 December 2022

27.

DocuSign Envelope 1D: 3099429-9B0BAESSAIA 60F63574201

APPENDIX E = COMMERCIAL DEVELOPMENT PLAN
FE BRT USC S200

NI License Application Number A.286-2020
Final
14 December 2022=»

*

Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made

a

al 3a

hi Wc

—+ TATvs
o% 1ese |—TTw
mT iesw |A—+ TA
Fame [251 ises |T
F——= 1»TvsToTo 1
«+

1T

»

1

vw

T

5»

1

sw ]

DocuSign Envelope 1D: 3096429-9B0 AESS AIAG. 60F635742G1

APPENDIX G ~ ROYALTY PAYMENT OPTIONS‘New Payment OptionsEffective March 2018
“The License Number MUST appear on payments, reports and correspondence.
(Credit and Debit Card Payments: Credit and debit ard payments can be submited for amounts up to $24,999.
Submit your payment through the U.S. Treasury web site located at:
tps:/wwwpay:gov/public/form/start
28680443.
Automated Clearing House (ACH) for payments through U.S. banks only
“The NIAID encourages its licensees to submit electronic funds transfer payments though the Automated Clearing
House (ACH). Submit your ACH payment through the U.S. Treasurywebsie located at
Tips:/Awwo. pay gov/public formysart 28680443. Please note that the NIAID “only” accepts ACH payments
through this U.S. Treasuryweb sic.
‘Electronic
FundsWireTransfers:“The following account information s provided for wire payments. In order to process payment via
Electronic Funds Wire Transfer sender MUST supply the following information within the transmission:
Drawn on a U.S. bank account via FEDWIRE
Please provide th following instructions (0 your Financial Institution for the remittance of Fedwire paymens
to the
NIHROYALTYFUND.
FedwireRequired Information
Fedwire Field Name
Lg
Losi;Thpesubype—[p2000; TAmownt[13400| Recciver ABA routing number*
Receiver ABA short nameBusiness Function Code

14200) | Beneficiary Identifier (account number)
TA200] | Beneficiary Name

Tweeenter paymentamowny

021030004“TREAS NYC
CTR (or CTP)

1||(enter 12digitgateway account 7)875080031006(enter agency name associated with The
Beneficiary Identifier)
DHHS / NIH (75080031(enter the name of the originatorof hepayment)
COMPANY NAME
T6000] | Originator to Beneficiary Information — Line 1 | (enter information o identify hepurpose ofhe.
payment)
ROYALTY
T6000] | Originator to Beneficiary Information — Line 2 | (enter information to iden he purpose ofhe.
payment)
LICENSE NUMBER
T6000] | Originator 0 Beneficiary Information — Line 3 | (enter information 0 ertythe purpose ofhe
payment)
INVOICE NUMBER
T6000] | Originator 0 Beneficiary Information — Line 4 | (enter information o denyhe purpose ofhe.
pamens)
Notes:“The financial institution address for Treasury's routing number is33 Liberty Sireet, New York, NY 100
NH License Application Number A.286-2020“30Final
14 December 2022

OscEnolgaID: IDEBZO00BAESSATABCORSE201-—«——[0510; TTypesSubype
Teo]

[hmm
Tonodoos
1
Ee
ss
a
iE
i
oe
ne

[ [S100] |ReceiverABA rowing mambo”[(3400} [Receiver ABAshortname
13600} |BusinessFunctionCode|TREASNVC|CTR(rCTP)||‘Originator to Beneficiary Information — Line 3 | (enter information to identify
the purposeof the‘Originator to Beneficiary Information — Line 4 | (enter information to identify
the purpose oftheDocuSan Envelope 10: 53099429-5B08-4ESSASS0FSB36F42C1

AgencyContacts
Office ofTechnology Transfer (OTT) (301) 4961057 OTT-Royalies@mailui gov
ChecksAll checks shouldbemade payable
to“NIH Patent Licensing”
Checks drawn on LS.bankaccount and sen by US Postal Service should be sen dirty to th following.
address
National Instiutesof Health
P.0.Box 979071
St Louis, MO 63197-9000‘Checks drawn on U.S. bank account and senbyovernight
orcouriershouldbeset to the following address:
US Bank
Goverment Lockbox SL-MO-C2GL
1005 Convention Plaza
St Louis, MO63101
Phone: 314-415-4087‘Checks drawn on aforeign
bankaccountshould be sent dire to the following address:
National Institutes of Health
Office ofTechnology Transfer
License Compliance and Administration
Royalty Administration
6701 Rockledge Drive
Suite 700, MSC 7788
Bethesda, Maryland 20892

NIH License Application Number A-286-2020
Final
14 December 2022

ae

£

i

i
ii
z

|
8

Gartifcate Of Compltion
Eero 1 SIOAENDIESAKBHOFISHF
ACTSit, Conta in DoS. NH Lar Amana or CourantA 2862020561
Soto
Oveoma Po. 55
Sopanens 1
Cantera on1——
cto Ered
Envlpald Samp: Eri

DocuSign

evre—
Enger
Nomen
Teton Sars
padi gio“TimeZone: (UTC-0500) Easter Time (US&Canada)pe]

Record Tracking
Ss Org
SgrerEvents
Snr cog
CrtSecu
Say ov Ema Act Anica

oct: Soin
Timestarp
Son RMR 521070
Sores. 142022852420

ar ona Borer
Sartre_SoponrerptopPressietos Sie
Usoaip
Ages
Saino

Eicon
Record oa
nd Signatur Disclosur:
ns
APSE
Sa
EditorDelivery Events
Statusmeas
Timestamp

Agent Delivery Events

Timestamp.

Statusintermediary Duivery Everts
StatusCortfed Delivery Events
StatusGarbon Copy Events
Statussoya
COPIEDecm
Tom Emo Rem Auancaton
Soy
Econ
Record poend Signatur Disclour:esWines Events
SartoreNotary Events
Signature
Envelope Summary Everts
StatusContaddorsd
Secu Crttos
SonyComps
SecuredCamaros
Sec creed
Payment Everts
StatusaTimestamp
Timestampi
progrTimestarp
Timestamp
Timestarps
Towazzasmon
Tonwazzaseizon
Tonwaizzassszon
Timestargs